VXX-401

About Vaxxinity

Vaxxinity is developing a next-generation immunotherapy platform to transform the treatment of chronic diseases and infectious threats. Its core AIM technology uses synthetic peptides to convert the body into its own 'drug factory,' stimulating targeted antibody production with a validated profile across billions of animal health doses and multiple human trials. The company is advancing a pipeline targeting large markets like Alzheimer's, Parkinson's, and COVID-19, with a strategic focus on creating accessible, scalable, and durable medicines that do not require complex frozen logistics.

Therapeutic Areas

Other Hypercholesterolemia Drugs